Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round.
So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets using drugs with stem cells.
– The market of veterinary biological medicines is very young. The first medicinal product in this category was authorized by the European Medicines Agency in 2017 – the preparation uses monoclonal antibodies to treat atopic dermatitis (…).
The entire article is available here: https://www.pb.pl/bioceltix-szykuje-sie-na-newconnect-1109200